Similar outcome after unrelated allogeneic peripheral blood stem cell transplantation compared with bone marrow in children and adolescents

Transplantation

Volumn 84, Issue 4, 2007, Pages 551-554

  Remberger, Mats ^a   Ringdén, Olle ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adolescents; BM; Children; PBSC

Indexed keywords

AMPHOTERICIN B; BUSULFAN; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; KETOCONAZOLE; METHOTREXATE; PREDNISOLONE; THYMOCYTE ANTIBODY;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DONOR; DRUG DOSE REDUCTION; ENGRAFTMENT; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INFECTION; LYMPHOMA; MALE; MORTALITY; NEUTROPHIL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; RELAPSE; SURVIVAL RATE; THROMBOCYTE; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; METHOTREXATE; PREDNISOLONE; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 34548167359     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000275184.41831.6d     Document Type: Article

References (26)

1. Hägglund H, Ringdén O, Öhman S, Remberger M, Carlens S, Mattsson J. A prospective randomized trial of Filgrastim (r-metHuG-CSF) given at different times after unrelated bone marrow transplantation. Bone Marrow Transplant 1998; 24: 831.
2. Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM. Peripheral blood stem cell donation: An analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (EBMT) databases. Bone Marrow Transplant 2001; 27: 689.
3. Remberger M, Ringdén O, Blau I, et al. No difference in graft-versus-host disease, relapse and survival comparing peripheral stem cells with bone marrow using unrelated donors. Blood 2001; 98: 1739.
4. Ottinger HD, Beelen DW, Scheulen B, Schaefer UW, Grosse-Wilde H. Improved immune reconstitution after allotransplantation of peripheral blood stem cells instead of bone marrow [see comments]. Blood 1996; 88: 2775.
5. Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomised trial [see comments]. Lancet 2000; 355: 1231.
6. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105: 548.
7. Champlin RE, Schmitz N, Horowitz MM, et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 2000; 95: 3702.
8. Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: A report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000; 18: 537.
9. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor [see comments]. Blood 1995; 85: 1655.
10. Schmitz N, Bacigalupo A, Labopin M, et al. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 1996; 95: 715.
11. Ringden O, Labopin M, Bacigalupo A, et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia. J Clin Oncol 2002; 20: 4655.
12. Eapen M, Horowitz MM, Klein JP, et al. Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: The Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol 2004; 22: 4872.
13. Olerup O, Zetterqvist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours. An alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 1992; 39: 225.
14. Ringdén O, Ruutu T, Remberger M, et al. A randomized trial comparing busulphan with total body irradiation as conditioning in allogenic marrow transplant recipient with leukemia. Blood 1994; 83: 2723.
15. Remberger M, Svahn B-M, Hentschke P, Löfgren C, Ringdén O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 823.
16. Ringdén O, Horowitz M, Sondel P. Methotrexate, cyclosporine or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia. Blood 1993; 18: 1094.
17. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. (11Review) (11 refs). Bone Marrow Transplant 1995; 15: 825.
18. Klein JP, Moeschberger ML. Survival Analysis: Techniques of Censored and Truncated Data, 2nd ed. New York: Springer-Verlag; 2003.
19. Pan L, Delmonte J Jr, Jalonen CK, Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422.
20. Ringdén O, Barret J, Zhang M-J, et al. Decreased treatment failure in recipients of HLA-identical bone marrow or peripheral blood stem cell transplants with high CD34 cell doses. Br J Haematol 2003; 121: 874.
21. Gorin NC, Labopin M, Rocha V, et al. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow. Blood 2003; 102: 3043.
22. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767.
23. Munker R, Schmid C, Madrigal JA, Kolb HJ. An update on graft-versus-host and graft-versus-leukemia reactions:Asummary of the sixth International Symposium held in Schloss Ellmau, Germany, January 22-24, 2004. Bone Marrow Transplant 2004; 34: 767.
24. Porter D, Levine JE. Graft-versus-host disease and graft-versus-leukemia after donor leukocyte infusion. Semin Hematol 2006; 43: 53.
25. Remberger M, Mattsson J, Hentschke P, et al. The graft-versus-leukaemia effect in haematopoietic stem cell transplantation using unrelated donors. Bone Marrow Transplant 2002; 30: 761.
26. Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555.